Section of Hepatobiliary-Pancreatic & Gastrointestinal Surgery

Medicine & Life Sciences

1. Pancreatic Neoplasms 100%
2. Adenocarcinoma 94%
3. Neoplasms 78%
4. Pancreaticoduodenectomy 72%
5. Pancreatectomy 64%
6. Survival 57%
7. sigma-2 receptor 41%
8. Pancreas 38%
9. Neoplasm Metastasis 30%
10. Liver 28%
11. gemcitabine 28%
12. Ligands 26%
13. Cholecystectomy 26%
14. Pancreatic Fistula 21%
15. SW IV-134 21%
16. Surgeons 21%
17. Laparoscopic Cholecystectomy 21%
18. Therapeutics 20%
19. Recurrence 18%
20. SV119 18%
21. Databases 17%
22. T-Lymphocytes 16%
23. Lymph Nodes 16%
24. Guidelines 16%
25. Macrophages 15%
26. Colorectal Neoplasms 14%
27. Neuroendocrine Tumors 14%
28. Neoadjuvant Therapy 14%
29. Stomach 14%
30. Hepatectomy 14%
31. mesothelin 14%
32. Cholangiocarcinoma 14%
33. Immunity 13%
34. Ovarian Neoplasms 13%
35. Drug Therapy 13%
36. Cell Death 13%
37. Mortality 13%
38. Proteins 13%
39. Bile Ducts 13%
40. Caspases 13%
41. Stomach Neoplasms 12%
42. Length of Stay 11%
43. Liver Neoplasms 11%
44. Wounds and Injuries 11%
45. Gastric Bypass 11%
46. Radiotherapy 11%
47. Radiofrequency Ablation 11%
48. Monocytes 11%
49. Apoptosis 11%
50. Practice Guidelines 11%
51. Vasculopathy, Retinal, With Cerebral Leukodystrophy 10%
52. Costs and Cost Analysis 10%
53. CD55 Antigens 10%
54. Myeloid-Derived Suppressor Cells 10%
55. Portal Vein 9%
56. Gallbladder Neoplasms 9%
57. Erythrocytes 9%
58. Morbidity 9%
59. Dendritic Cells 9%
60. Complement System Proteins 9%
61. Immunotherapy 9%
62. Membranes 9%
63. Mitochondria 9%
64. Pancreatic Ducts 9%
65. Melanoma 8%
66. Lymph Node Ratio 8%
67. Jaundice 8%
68. Gallbladder 8%
69. Hepatocellular Carcinoma 8%
70. Oxaliplatin 8%
71. Herniorrhaphy 8%
72. Multivariate Analysis 8%
73. Immunization 8%
74. Patient Readmission 8%
75. Residual Neoplasm 7%
76. Splenic Artery 7%
77. Disease-Free Survival 7%
78. Protein Deficiency 7%
79. DNA 7%
80. Klatskin Tumor 7%
81. Piperazine 7%
82. Postoperative Complications 7%
83. Splenic Vein 6%
84. Exonucleases 6%
85. Robotics 6%
86. Prospective Studies 6%
87. Operative Time 6%
88. Cell Line 6%
89. Blood Vessels 6%
90. Safety 6%
91. Chronic Pancreatitis 6%
92. Neck 6%
93. Propensity Score 6%
94. Swine 6%
95. human exonuclease 5 6%
96. Gastric Emptying 6%
97. Immunosuppressive Agents 6%
98. Nomograms 6%
99. Single-Chain Antibodies 6%
100. Pharmaceutical Preparations 6%